In the last trading session, 4.02 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.31. With the company’s per share price at $1.23 changed hands at $0.0 or 0.00% during last session, the market valuation stood at $256.64M. SGMO’s last price was a discount, traded about -158.54% off its 52-week high of $3.18. The share price had its 52-week low at $0.30, which suggests the last value was 75.61% up since then. When we look at Sangamo Therapeutics Inc’s average trading volume, we note the 10-day average is 3.83 million shares, with the 3-month average coming to 7.98 million.
Analysts gave the Sangamo Therapeutics Inc (SGMO) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.88. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended SGMO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
The company’s shares are showing year-to-date upside of 20.59%, with the 5-day performance at 6.03% in the green. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is -47.44% down. Looking at the short shares, we see there were 22.45 million shares sold at short interest cover period of 1.97 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2.5, meaning bulls need an upside of 50.8% from its current market value. According to analyst projections, SGMO’s forecast low is 2 with 3 as the target high. To hit the forecast high, the stock’s price needs a -143.9% plunge from its current level, while the stock would need to soar -62.6% for it to hit the projected low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Data shows that the Sangamo Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 57.17% over the past 6 months, a 22.03% in annual growth rate that is considerably higher than the industry average of 15.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.96%. The 2025 estimates are for Sangamo Therapeutics Inc earnings to increase by 68.41%.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next quarterly earnings report in March.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.38% of Sangamo Therapeutics Inc shares while 24.64% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 25.24%. There are 24.64% institutions holding the Sangamo Therapeutics Inc stock share, with WASATCH ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 11.1403% of the shares, roughly 20.09 million SGMO shares worth $7.2 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 7.7963% or 14.06 million shares worth $5.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Wasatch Ultra Growth Fund and Wasatch Microcap Fund . With 10.97 shares estimated at $13.5 million under it, the former controlled 5.26% of total outstanding shares. On the other hand, Wasatch Microcap Fund held about 2.71% of the shares, roughly 5.65 shares worth around $6.95 million.
